DeepMed Research

RTOG Foundation, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.rtog.org

Clinical Trials

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: Temozolomide 150 mg x 5 days
Drug: temozolomide 60 mg x 21 days
Drug: temozolomide 75 mg x 21 days
Drug: ABT-888 20 mg x 21 days
Drug: ABT-888 40 mg x 21 days
Drug: ABT-888 40 mg x 5 days

First Posted Date: 2009-12-04

Last Posted Date: 2017-07-02

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 257

Registration Number: NCT01026493

Locations: 🇺🇸
Renown Institute for Cancer at Renown Regional Medical Center, Reno, Nevada, United States
🇺🇸
Louisville Oncology at Norton Cancer Institute - Louisville, Louisville, Kentucky, United States
🇺🇸
Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States

and more 14 locations

Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Phase 1

Withdrawn

Conditions: Pancreatic Cancer

First Posted Date: 2009-11-23

Last Posted Date: 2013-06-24

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT01017822

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: cisplatin
Drug: 5-fluorouracil
Drug: Mitomycin
Radiation: Three-Dimensional Conformal Radiation Therapy

First Posted Date: 2009-09-22

Last Posted Date: 2024-04-29

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 37

Registration Number: NCT00981656

Locations: 🇺🇸
Barberton Citizens Hospital, Barberton, Ohio, United States
🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States

and more 10 locations

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Phase 3

Active, not recruiting

Conditions: Cervical Cancer

Interventions: Drug: cisplatin
Drug: carboplatin
Radiation: intensity-modulated radiation therapy
Radiation: standard external beam radiation therapy
Drug: paclitaxel
Radiation: Optional brachytherapy boost

First Posted Date: 2009-09-21

Last Posted Date: 2024-11-26

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 236

Registration Number: NCT00980954

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

and more 122 locations

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: panitumumab
Drug: paclitaxel
Procedure: surgery

First Posted Date: 2009-09-17

Last Posted Date: 2022-06-15

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 71

Registration Number: NCT00979212

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States
🇺🇸
Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California, United States

and more 28 locations

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Radiation: Single-fraction stereotactic body radiation therapy (SBRT)
Radiation: Multiple-fraction stereotactic body radiation therapy (SBRT)

First Posted Date: 2009-08-18

Last Posted Date: 2020-03-04

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 94

Registration Number: NCT00960999

Locations: 🇺🇸
Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States
🇺🇸
Parkview Regional Cancer Center at Parkview Health, Fort Wayne, Indiana, United States
🇺🇸
Dale and Frances Hughes Cancer Center at Pocono Medical Center, East Stroudsburg, Pennsylvania, United States

and more 35 locations

RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Phase 3

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Biological: cetuximab
Radiation: intensity-modulated radiation therapy

First Posted Date: 2009-08-11

Last Posted Date: 2024-05-28

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 702

Registration Number: NCT00956007

Locations: 🇺🇸
John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
Mercy San Juan Medical Center, Carmichael, California, United States
🇺🇸
University of Southern California/Norris Cancer Center, Los Angeles, California, United States

and more 260 locations

Depression Screening in Patients Undergoing Radiation Therapy For Cancer

Completed

Conditions: Depression
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2009-08-04

Last Posted Date: 2015-03-18

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 463

Registration Number: NCT00951184

Locations: 🇺🇸
Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States
🇺🇸
St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States
🇺🇸
CCOP - North Shore University Hospital, Manhasset, New York, United States

and more 13 locations

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Radiation: Dose-Escalated Radiation Therapy
Drug: bicalutamide
Drug: flutamide
Drug: LHRH agonist (antagonist) therapy

First Posted Date: 2009-07-10

Last Posted Date: 2024-10-10

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 1538

Registration Number: NCT00936390

Locations: 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States

and more 514 locations

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Phase 3

Completed

Conditions: Sexual Dysfunction
Prostate Cancer

Interventions: Other: Placebo
Drug: Tadalafil

First Posted Date: 2009-07-02

Last Posted Date: 2018-02-14

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 242

Registration Number: NCT00931528

Locations: 🇺🇸
Providence Hospital, Mobile, Alabama, United States
🇺🇸
Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 189 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy